Oct 15, 2018 - Hip fracture is a serious and growing healthcare problem that is in desperate need of focus.1-year mortality rates in patients post hip fracture repair are high and need to be addressed.Improvements i
Oct 08, 2018 - bluebird's marketing authorization application (MAA) for its experimental gene therapy, LentiGlobin, was accepted by the regulatory body in Europe.
Oct 05, 2018 - Zacks.com highlights: MCBC Holdings, Newpark Resources, Cigna, Weight Watchers International and Ligand Pharmaceuticals
Oct 04, 2018 - Alnylam Pharmaceuticals (ALNY) submits a Clinical Trial Authorization application in the U.K. to start a phase I/II study on its early stage candidate, ALN-AAT02, for treating alpha-1 liver disease.
Oct 04, 2018 - VistaGen (VTGN) Fast Track designation for its pipeline candidate, AV-101, for treating neuropathic pain.
Oct 03, 2018 - Amgen (AMGN) gains an FDA approval for its sNDA with respect to a once-weekly dosing option of its multiple myeloma drug Kyprolis (70 mg/m2) combined with dexamethasone (Kd).
Oct 03, 2018 - Paratek (PRTK) gets FDA approval for Nuzyra for the treatment of serious community-acquired bacterial infections and Seysara for the treatment of acne.
Oct 01, 2018 - Insmed's (INSM) lung infection drug Arikayce gains an accelerated approval from the FDA for the treatment of lung disease caused by mycobacterium avium complex (MAC).
Sep 28, 2018 - Ultragenyx (RARE) reports encouraging top-line data from two cohorts of the study evaluating its adeno-associated virus ("AAV") gene therapy candidate -- DTX301.
Sep 27, 2018 - Ligand Pharmaceuticals (LGND) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.